Overview

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors.
Phase:
Phase 4
Details
Lead Sponsor:
Kettering Health Network
Collaborators:
Abiant, Inc.
Sunovion
Treatments:
Eszopiclone
Zolpidem